Literature DB >> 24535075

Analysis of reasons for osteonecrosis of the jaws.

Christian Walter1, Keyvan Sagheb, Jennifer Bitzer, Roman Rahimi-Nedjat, Katherine Joyce Taylor.   

Abstract

PURPOSE: Osteonecroses of the jaws are caused by several reasons. Bisphosphonate-associated osteonecrosis of the jaws (BP-ONJ) is known since 2003 with an increasing incidence in the first years. Along with more knowledge about the pathophysiology, preventive strategies were implemented trying to reduce the incidence. The aim of this retrospective study was to analyze the frequency and overall proportion of BP-ONJ within the field of osteonecrosis. The data was compared to a similar study performed in 2005.
METHODS: All patients with osteonecrosis or osteomyelitis treated in the period from April 2005 to July 2012 in the Oral and Maxillofacial Surgery at the University of Mainz, Germany, were analyzed.
RESULTS: The reasons for osteonecrosis were bisphosphonates in 45 %, odontogenic or surgically induced osteonecrosis in 32 %, osteoradionecrosis in 17 %, traumas in 1 %, and in 4 % the reason remained unclear. The BP-ONJ became the most important factor for osteonecrosis. Its fraction in the years 2000-2005 was 10 % only.
CONCLUSIONS: Although preventive strategies are implemented, the number of new cases got bigger. The implemented prevention strategies did not manage to reduce the overall number of new cases. Furthermore, the launch of other medications with a similar side effect on the jawbone as the BP-ONJ for bisphosphonates might influence the overall distribution of osteonecroses.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24535075     DOI: 10.1007/s00784-014-1205-6

Source DB:  PubMed          Journal:  Clin Oral Investig        ISSN: 1432-6981            Impact factor:   3.573


  24 in total

Review 1.  Bisphosphonates: prevention of bone metastases in breast cancer.

Authors:  Michael Gnant; Peter Dubsky; Peyman Hadji
Journal:  Recent Results Cancer Res       Date:  2012

2.  American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update.

Authors:  Salvatore L Ruggiero; Thomas B Dodson; Leon A Assael; Regina Landesberg; Robert E Marx; Bhoomi Mehrotra
Journal:  J Oral Maxillofac Surg       Date:  2009-05       Impact factor: 1.895

3.  The influence of bisphosphonates on viability, migration, and apoptosis of human oral keratinocytes--in vitro study.

Authors:  Andreas M Pabst; Thomas Ziebart; Felix P Koch; Katherine Y Taylor; Bilal Al-Nawas; Christian Walter
Journal:  Clin Oral Investig       Date:  2011-01-12       Impact factor: 3.573

4.  Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer.

Authors:  Valentina Guarneri; David Miles; Nicholas Robert; Véronique Diéras; John Glaspy; Ian Smith; Christoph Thomssen; Laura Biganzoli; Tanya Taran; PierFranco Conte
Journal:  Breast Cancer Res Treat       Date:  2010-04-02       Impact factor: 4.872

5.  Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.

Authors:  David H Henry; Luis Costa; Francois Goldwasser; Vera Hirsh; Vania Hungria; Jana Prausova; Giorgio Vittorio Scagliotti; Harm Sleeboom; Andrew Spencer; Saroj Vadhan-Raj; Roger von Moos; Wolfgang Willenbacher; Penella J Woll; Jianming Wang; Qi Jiang; Susie Jun; Roger Dansey; Howard Yeh
Journal:  J Clin Oncol       Date:  2011-02-22       Impact factor: 44.544

6.  Geranylgeraniol - a new potential therapeutic approach to bisphosphonate associated osteonecrosis of the jaw.

Authors:  T Ziebart; F Koch; M O Klein; J Guth; J Adler; A Pabst; B Al-Nawas; C Walter
Journal:  Oral Oncol       Date:  2011-01-17       Impact factor: 5.337

7.  Use of Ultrasonic Bone Surgery (Piezosurgery) to Surgically Treat Bisphosphonate-Related Osteonecrosis of the Jaws (BRONJ). A Case Series Report with at Least 1 Year of Follow-Up.

Authors:  Cornelio Blus; Serge Szmukler-Moncler; Giulio Giannelli; Gloria Denotti; Germano Orrù
Journal:  Open Dent J       Date:  2013-08-23

8.  Influence of bisphosphonates on endothelial cells, fibroblasts, and osteogenic cells.

Authors:  C Walter; M O Klein; A Pabst; B Al-Nawas; H Duschner; T Ziebart
Journal:  Clin Oral Investig       Date:  2009-03-18       Impact factor: 3.573

9.  Radiologic bone loss in patients with bisphosphonate-associated osteonecrosis of the jaws: a case-control study.

Authors:  Christian Walter; Christian Laux; Keyvan Sagheb
Journal:  Clin Oral Investig       Date:  2013-03-23       Impact factor: 3.573

10.  Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate.

Authors:  Christian Walter; Bilal Al-Nawas; Knut A Grötz; Christian Thomas; Joachim W Thüroff; Viktoria Zinser; Heinold Gamm; Joachim Beck; Wilfried Wagner
Journal:  Eur Urol       Date:  2008-06-26       Impact factor: 20.096

View more
  14 in total

1.  Isoprenoid geranylgeraniol: the influence on cell characteristics of endothelial progenitor cells after bisphosphonate therapy in vitro.

Authors:  A M Pabst; M Krüger; T Ziebart; C Jacobs; C Walter
Journal:  Clin Oral Investig       Date:  2015-01-16       Impact factor: 3.573

2.  A retrospective study of osteomyelitis and osteonecrosis of the jaws and its etiologic implication of bisphosphonate in Asians.

Authors:  Sung Ok Hong; Chae-Yoon Lee; Junho Jung; Deog-Yoon Kim; Christian Walter; Yong-Dae Kwon
Journal:  Clin Oral Investig       Date:  2016-10-22       Impact factor: 3.573

3.  The influence of geranylgeraniol on microvessel sprouting after bisphosphonate substitution in an in vitro 3D-angiogenesis assay.

Authors:  A M Pabst; M Krüger; K Sagheb; T Ziebart; C Jacobs; S Blatt; E Goetze; C Walter
Journal:  Clin Oral Investig       Date:  2016-05-12       Impact factor: 3.573

Review 4.  Is serum C-terminal telopeptide cross-link of type 1 collagen a reliable parameter for predicting the risk of medication-related osteonecrosis of the jaws? A systematic review and meta-analysis of diagnostic test accuracy.

Authors:  Bassel Traboulsi-Garet; Adrià Jorba-García; Octavi Camps-Font; Fabio Abreu Alves; Rui Figueiredo; Eduard Valmaseda-Castellón
Journal:  Clin Oral Investig       Date:  2022-02-06       Impact factor: 3.573

5.  Bone scintigraphy predicts bisphosphonate-induced osteonecrosis of the jaw (BRONJ) in patients with metastatic castration-resistant prostate cancer (mCRPC).

Authors:  Christian Thomas; Magdalena Spanidis; Christina Engel; Frederik C Roos; Sebastian Frees; Andreas Neisius; Christian Hampel; Peter Rubenwolf; Joachim W Thüroff; Christian Walter; Matthias Miederer
Journal:  Clin Oral Investig       Date:  2015-08-26       Impact factor: 3.573

Review 6.  Dental implants in patients treated with antiresorptive medication - a systematic literature review.

Authors:  Christian Walter; Bilal Al-Nawas; Tim Wolff; Eik Schiegnitz; Knut A Grötz
Journal:  Int J Implant Dent       Date:  2016-04-04

7.  Diabetes Mellitus and Its Association to the Occurrence of Medication-Related Osteonecrosis of the Jaw.

Authors:  Roman K Rahimi-Nedjat; Keyvan Sagheb; Andreas Pabst; Lukas Olk; Christian Walter
Journal:  Dent J (Basel)       Date:  2016-05-31

8.  Osteoclast profile of medication-related osteonecrosis of the jaw secondary to bisphosphonate therapy: a comparison with osteoradionecrosis and osteomyelitis.

Authors:  Christian Gross; Manuel Weber; Kay Creutzburg; Patrick Möbius; Raimund Preidl; Kerstin Amann; Falk Wehrhan
Journal:  J Transl Med       Date:  2017-06-06       Impact factor: 5.531

9.  Non-Radiation-Related Osteonecrosis of the Jaws in Dogs: 14 Cases (1996-2014).

Authors:  Santiago Peralta; Boaz Arzi; Ana Nemec; Milinda J Lommer; Frank J M Verstraete
Journal:  Front Vet Sci       Date:  2015-05-05

10.  Bisphosphonate related osteonecrosis of the jaws (BRONJ) in osteoporotic males.

Authors:  Yong-Dae Kwon; Chae-Yoon Lee; Sung Ok Hong; Yeon-Ah Lee; Joo-Young Ohe; Deog-Yoon Kim
Journal:  Springerplus       Date:  2016-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.